Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

70
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
70
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

84
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
84
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

81
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
81
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

116
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
116
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

96
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
96
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

54
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
54

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vapors, gases, dusts and fumes at work and chronic obstructive pulmonary disease/bronchitis: a systematic review and meta-analyses.

Journal of occupational medicine and toxicology (London, England)·2026
Same author

Characterizing updated and living meta-analyses Part 1: A methodological scoping review on methods for conducting meta-analyses in updated and living systematic reviews.

Journal of clinical epidemiology·2026
Same author

Editors' Choice: July 2026.

Journal of clinical epidemiology·2026
Same author

Protocol for a SPIRIT extension for reporting Pragmatic and Explanatory trial protocols designed using the PRECIS tool. (SPIRIT-PRECIS).

Journal of clinical epidemiology·2026
Same author

Facilitators and barriers to engaging patient partners in knowledge syntheses: A stage-based approach.

Research synthesis methods·2026
Same author

Protocol for a CONSORT extension for reporting Pragmatic and Explanatory trials designed using the PRECIS tool. (CONSORT-PRECIS).

Journal of clinical epidemiology·2026
Same journal

Integrating health economics and implementation science: a call to action.

BMC medical research methodology·2026
Same journal

Methods for incorporating test result information within the high-dimensional propensity score framework: application in UK electronic health record data.

BMC medical research methodology·2026
Same journal

Sparse multi-way DMDC for longitudinal classification in high dimension low sample size data.

BMC medical research methodology·2026
Same journal

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

BMC medical research methodology·2026
Same journal

Comparative evaluation of interrupted time series analytical methods for healthcare quality improvement research: a Monte Carlo simulation study.

BMC medical research methodology·2026
Same journal

Methodological advances in claims-based dementia algorithms: integrating medication and clinical data for medicare populations.

BMC medical research methodology·2026
See all related articles

Related Experiment Video

Updated: Nov 16, 2025

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

8.9K

Using a distribution-based approach and systematic review methods to derive minimum clinically important differences.

Jennifer A Watt1,2, Areti Angeliki Veroniki3,4,5, Andrea C Tricco3

  • 1Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital- Unity Health Toronto, 209 Victoria Street, East Building, Room 723, Toronto, Ontario, M5B 1W8, Canada. jennifer.watt@utoronto.ca.

BMC Medical Research Methodology
|February 27, 2021
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for determining the minimum clinically important difference (MCID) for clinical scales using meta-analysis data. This distribution-based approach approximates established MCIDs, improving the interpretation of treatment effects in dementia research.

Keywords:
Alzheimer disease assessment scale – cognitive subscaleBack-transformationMeta-analysisMini-mental state examMinimum clinically important differenceSystematic review

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.1K
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

29.5K

Related Experiment Videos

Last Updated: Nov 16, 2025

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

8.9K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.1K
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

29.5K

Area of Science:

  • Medical Statistics
  • Clinical Trials
  • Systematic Reviews

Background:

  • Clinical interpretation of scale changes relies on Minimum Clinically Important Difference (MCID).
  • Traditional MCID determination methods involve individual studies or expert opinion.
  • A novel approach using meta-analytic data could enhance clinical understanding of treatment effects.

Purpose of the Study:

  • To approximate MCIDs using a distribution-based approach.
  • To pool Standard Deviations (SDs) from randomized trials for cognitive scales in dementia.
  • To compare derived MCIDs with previously published values for MMSE and ADAS-Cog.

Main Methods:

  • Pooled SDs from parallel randomized trials (RCTs) included in a systematic review of dementia medications.
  • Calculated MCIDs at 0.4 and 0.5 SDs using pooled baseline or mean change SDs for Mini-Mental State Exam (MMSE) and Alzheimer Disease Assessment Scale - Cognitive Subscale (ADAS-Cog).
  • Excluded RCTs lacking baseline or mean change SD values.

Main Results:

  • Distribution-based MCIDs approximated published MCIDs for MMSE and ADAS-Cog.
  • For MMSE (51 RCTs, 12,449 patients), derived MCIDs ranged from 1.4 to 2.0.
  • For ADAS-Cog (37 RCTs, 10,006 patients), derived MCIDs ranged from 2.6 to 5.0.

Conclusions:

  • A distribution-based approach using systematic review data effectively approximated known MCIDs.
  • Deriving MCIDs from baseline SDs yielded better results than from mean change SDs.
  • This method can aid in the clinical interpretation of outcome measures in RCTs and systematic reviews.